The government has significantly simplified drug development and clinical research approvals, with the Union Ministry of Health and Family Welfare notifying key amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019. The reforms aim to reduce regulatory burdens, shorten approval timelines, and improve Ease of Doing Business, while safeguarding public health. The changes align with directives to accelerate pharmaceutical innovation and strengthen India’s position as a global hub for drug R&D.
Test Licences Replaced with Faster Intimation Process
Under the amended rules, pharmaceutical companies no longer require a test licence from the Central Drugs Standard Control Organization (CDSCO) to manufacture small, non-commercial quantities of drugs for research, testing, or analysis. Instead, companies can proceed after submitting a prior online intimation to CDSCO. However, this exemption does not apply to high-risk drugs, including cytotoxic drugs, narcotics, and psychotropic substances, for which licensing requirements will continue. Officials estimate that this reform could save at least 90 days in the drug development lifecycle, offering a significant boost to research timelines and innovation. For drug categories where test licences remain mandatory, the statutory processing time has been reduced from 90 days to 45 days. Considering that CDSCO handles 30,000–35,000 test licence applications annually, the reform is expected to substantially ease regulatory pressure across the sector.
Faster Clinical Studies for Generics
Another key reform removes the requirement for prior approval for certain low-risk Bioavailability and Bioequivalence (BA/BE) studies. Companies can now initiate these studies after a simple online intimation to CDSCO, enabling faster start-up, particularly for the generic pharmaceutical industry, which relies heavily on BA/BE trials. CDSCO processes around 4,000–4,500 BA/BE study applications annually, and the revised system is expected to sharply reduce procedural delays, accelerating clinical research timelines.
Digital-First Implementation for Seamless Compliance
To support smooth implementation, the government will introduce new online modules on the National Single Window System (NSWS) and the SUGAM portal. These platforms will allow companies to submit intimations transparently and efficiently, while enabling CDSCO to optimise manpower and improve regulatory efficiency without compromising oversight.
Strengthening India’s Global R&D Leadership
The Ministry of Health emphasized that the amendments balance regulatory trust with safety, allowing faster testing, review, and initiation of studies across the drug development continuum. “These reforms reinforce India’s commitment to trust-based regulation, aligned with the Jan Vishwas Siddhant and global best practices,” the Ministry said. As reported by devdiscourse.com, by reducing timelines and compliance costs, the government aims to promote R&D-led growth, support innovation in the pharmaceutical sector, and enhance India’s attractiveness as a preferred destination for global drug research and development.
